Literature DB >> 10202212

Role of opioid ligands in the irritable bowel syndrome.

E Corazziari1.   

Abstract

Endogenous opioid peptides - enkephalins, beta-endorphin and dynorphins - are located in specific sites of the brain, the spinal cord, the autonomic ganglia and the enteric nervous system. Endogenous opioids participate in the regulation of nervous visceral afference and sensitivity as well as of several visceral motor function induced by the central nervous system and through the enteroenteric and the myoenteric reflexes. Their final effect on gut physiology is the net and harmonically balanced result of their binding to mu, delta and kappa opioid receptor subtypes. Exogenous opioid receptor ligands with different affinities for the opioid receptor subtypes have been effectively used to modify and normalize altered gut functions. The mu receptor agonists - morphine and, to a greater extent, the meperidine congeners diphenoxylate and loperamide - have been shown to slow gastrointestinal transit by their effects on the circular and longitudinal muscle of the intestine. Diphenoxylate and, more efficiently, loperamide, for the lack of any effect on the central nervous system, have been usefully employed in the treatment of diarrhea in irritable bowel syndrome (IBS) patients. Unlike the mu receptor agonists morphine and loperamide, which invariably stimulate colonic motility, trimebutine, which has almost equal affinity for mu, delta and kappa receptors, has no effect on normal colonic activity but reduces the abnormal increase in postprandial motor activity in IBS patients and accelerates slow large bowel transit in constipated patients. Opioid ligands can be usefully employed to normalize altered visceral sensitivity in IBS patients. The kappa receptor agonist fedotozine exerts its antinociceptive effect by acting on peripheral nerve endings of sensory vagal and nonvagal afferent pathways. Fedotozine has been shown to increase the threshold of perception to colonic distension in experimental conditions and to affect favourably symptoms of IBS in clinical trials.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10202212     DOI: 10.1155/1999/598659

Source DB:  PubMed          Journal:  Can J Gastroenterol        ISSN: 0835-7900            Impact factor:   3.522


  15 in total

1.  Successful Treatment with Methylnaltrexone and IVIG for Paraneoplastic Syndrome-Associated Intestinal Pseudo-Obstruction.

Authors:  Cheng Zhang; Niravkumar J Patel; W Carl Jacobs; Sonal Ullman; Tyler M Berzin; Ram Chuttani; Anthony J Lembo; Jacqueline L Wolf
Journal:  Gastroenterol Hepatol (N Y)       Date:  2013-01

Review 2.  Opioid analgesics and P-glycoprotein efflux transporters: a potential systems-level contribution to analgesic tolerance.

Authors:  Susan L Mercer; Andrew Coop
Journal:  Curr Top Med Chem       Date:  2011       Impact factor: 3.295

3.  Prostatic relaxation induced by loperamide is mediated through activation of opioid μ-2 receptors in vitro.

Authors:  Chih-Cheng Lu; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  Exp Ther Med       Date:  2011-01-20       Impact factor: 2.447

Review 4.  The role of experimental models in developing new treatments for irritable bowel syndrome.

Authors:  Daniel P Holschneider; Sylvie Bradesi; Emeran A Mayer
Journal:  Expert Rev Gastroenterol Hepatol       Date:  2011-02       Impact factor: 3.869

5.  Opiate-induced constipation related to activation of small intestine opioid μ2-receptors.

Authors:  Wency Chen; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  World J Gastroenterol       Date:  2012-03-28       Impact factor: 5.742

6.  Current insights in to the pathophysiology of Irritable Bowel Syndrome.

Authors:  Theodoros Karantanos; Theofano Markoutsaki; Maria Gazouli; Nicholas P Anagnou; Dimitrios G Karamanolis
Journal:  Gut Pathog       Date:  2010-05-13       Impact factor: 4.181

Review 7.  Functional GI disorders: from animal models to drug development.

Authors:  E A Mayer; S Bradesi; L Chang; B M R Spiegel; J A Bueller; B D Naliboff
Journal:  Gut       Date:  2007-10-26       Impact factor: 23.059

Review 8.  Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome.

Authors:  Lisa Ruepert; A Otto Quartero; Niek J de Wit; Geert J van der Heijden; Gregory Rubin; Jean Wm Muris
Journal:  Cochrane Database Syst Rev       Date:  2011-08-10

9.  Prostatic relaxation induced by loperamide is reduced in spontaneously hypertensive rats.

Authors:  Liang-Ming Lee; Chih-Cheng Lu; Hsien-Hui Chung; Juei-Tang Cheng
Journal:  ScientificWorldJournal       Date:  2012-05-03

10.  Drug development for the irritable bowel syndrome: current challenges and future perspectives.

Authors:  Fabrizio De Ponti
Journal:  Front Pharmacol       Date:  2013-02-01       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.